Bioton SA (WAR:BIO)

QUOTE AND NEWS
FierceBiotech  Sep 7  Comment 
With a deal on the table to buy up a 51 percent stake in Poland's Bioton, Actavis says it wants to use the move as a springboard into biosimilars. Like a slate of biopharma companies, the Icelandic generic drugmaker sees a big future for companies...




RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS

BIOTON S.A. sells finished goods, commodities and services through BIOTON TRADE Sp. o.o., a pharmaceutical wholesale company incorporated in 1998. Subsequent distribution takes place through other pharmaceutical wholesalers and pharmacies.

Distribution in Poland The Company’s internal and external sales forces are responsible for marketing and distribution within Poland. BIOTON S.A.'s sales and marketing departments primarily aim to boost sales and ensure efficient and effective distribution so that BIOTON products are readily available everywhere in Poland. BIOTON has long enjoyed a leading position in most segments of the pharmaceutical market in which it operates thanks to the efficient organisation of its sales force.

Foreign distribution In line with its global expansion strategy, BIOTON S.A. registers its products in various countries around the world. Products are sold on foreign markets under co-operation agreements and sales agreements concluded with foreign and domestic partners. Members of the BIOTON Group pursue innovative projects whose performance and commercialisation supports common development.

BIOTON aims to reinforce its position of a biotechnological company with a global reach. The Company is able to pursue its strategic objectives of protecting Patients’ health and improving the quality of their lives by participating in research and development projects, promoting the expansion of its product portfolio and making well-informed business decisions. BIOTON fulfils its stated mission by implementing strategies and development plans aimed at:

   * reinforcing BIOTON's status on the Polish insulin market
   * promoting BIOTON's insulin world-wide by maximising its share of the existing markets and entering new ones
   * developing innovative, clinically important medicinal products, including biotechnological drugs developed by members of the BIOTON Group
   * expanding BIOTON’s generic drug portfolio.

[1]

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki